1764eP A multi-omic liquid biopsy for early colorectal cancer detection

Abstract

Background
Colorectal cancer (CRC) is one of the most common and deadliest cancers worldwide, and incidence rates are rising. However, early detection and intervention can improve the survival rates and quality of life of affected patients. The preferred screening choice is still debated, due to the lack of available resources and the invasiveness of colonoscopy, and the relatively low sensitivity of stool-based tests. Blood-based CRC detection offers an attractive screening strategy...

Methods
The Dxcover Liquid Biopsy Platform is a rapid multi-omic liquid biopsy that interrogates a blood sample with Infrared (IR) radiation and produces a distinctive signature that represents the whole biomolecular profile of the sample. The technique analyzes the full range of diagnostic information from both the tumor and the non-tumor response. CREATE-2 is a prospective, multicenter, case-control study, with collection sites across the USA and the UK. Blood was drawn either pre-colonoscopy or...

Results
The US data (n=960) generated a receiver operating characteristic curve (ROC) curve with an area under the curve (AUC) of 0.96, with 91% for both sensitivity and specificity. Furthermore, 100% of stage I and II CRC were detected (n=18). For the UK cohort (n=306), the spectral data was combined with the patients’ FIT results, which produced an AUC of 0.89. The sensitivity-tuned model produced high sensitivities across all stages: I 89%; II 93%; III 90%; IV 100%. At 90% specificity, the model...

Conclusions
A rapid liquid biopsy that is sensitive to early-stage CRC could substantially improve patient outcomes. Current screening programs have addressable limitations, and the emergence of new alternative technologies is vital to support earlier CRC detection...